+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

319Pthe role of cetuximab maintenance after chemotherapy in patients with recurrent/metastatic squamous cell carcinoma of head and neck (R/M Scchn): A retrospective analysis



319Pthe role of cetuximab maintenance after chemotherapy in patients with recurrent/metastatic squamous cell carcinoma of head and neck (R/M Scchn): A retrospective analysis



Annals of Oncology 26(Suppl 9): ix95.1-ix95




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 067408756

Download citation: RISBibTeXText

DOI: 10.1093/annonc/mdv527.06


Related references

Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN): An interim analysis. Journal of Clinical Oncology 26(15_Suppl): 6072-6072, 2016

Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Annals of Oncology 25(4): 801-807, 2014

TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO). Annals of Oncology 26(3): 561-567, 2016

Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Investigational New Drugs 32(6): 1278-1284, 2015

Poster Efficacy of Cetuximab Alone or in Combination With Docetaxel as Second-line Treatment in Patients With Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (Scchn). European Journal of Cancer 47: S568-S569, 2011

Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) (EXTREME). Journal of Clinical Oncology 24(18_Suppl): 5537-5537, 2016

Spectrum, a phase Iii trial for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (Scchn) receiving chemotherapy with or without panitumumab: interim pooled safety analysis. European Journal of Cancer Suppl.s 7(2): 474-475, 2009

Cetuximab in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies. Journal of Clinical Oncology 23(16_Suppl): 5505-5505, 2016

Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer. Head and Neck 35(10): 1471-1474, 2014

Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Oncotargets and Therapy 6: 1507-1514, 2013

Phase 1b Trial of TLR8 Agonist VTX-2337 in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN). International Journal of Radiation Oncology*biology*physics 88(2): 503-504, 2014

A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clinical Oncology ) 17(6): 418-424, 2005

Cetuximab plus platinum-based therapy first-line in recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety results of a randomized phase III trial (EXTREME). EJC Suppl.s 5(4): 324, 2007

Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens. Oral Oncology 46(11): 818-821, 2011

Cetuximab-Carboplatin-5-Fluorouracil Regimen in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A French Retrospective Survey. Oncology 93(1): 11-17, 2017